vs
亚什兰（ASH）与泰尼特医疗（HCSG）财务数据对比。点击上方公司名可切换其他公司
泰尼特医疗的季度营收约是亚什兰的1.2倍（$466.7M vs $386.0M），泰尼特医疗同比增速更快（6.6% vs -4.7%），亚什兰自由现金流更多（$111.0M vs $16.0M），过去两年泰尼特医疗的营收复合增速更高（5.0% vs -18.1%）
亚什兰是一家总部位于美国特拉华州威尔明顿的化工企业，1924年始创于肯塔基州亚什兰市，最初以炼油业务起家，1994年迁至现总部。公司拥有多个业务板块，覆盖化工中间体与溶剂、复合材料、工业特种化学品、个人及家居护理、制药、食品饮料以及农业相关领域，2017年之前曾是胜牌润滑油的主要生产商。
泰尼特医疗集团是一家总部位于达拉斯的美国上市营利性跨国医疗服务企业，旗下通过品牌、子公司、合资企业及合作项目（包括联合外科合作伙伴国际USPI），运营着65家医院与超450家医疗机构，此外还经营康尼弗医疗解决方案，为医疗系统及其他客户提供医疗配套服务支持。
ASH vs HCSG — 直观对比
营收规模更大
HCSG
是对方的1.2倍
$386.0M
营收增速更快
HCSG
高出11.3%
-4.7%
自由现金流更多
ASH
多$95.0M
$16.0M
两年增速更快
HCSG
近两年复合增速
-18.1%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $386.0M | $466.7M |
| 净利润 | $-12.0M | — |
| 毛利率 | 27.2% | 15.4% |
| 营业利润率 | -1.6% | 6.1% |
| 净利率 | -3.1% | — |
| 营收同比 | -4.7% | 6.6% |
| 净利润同比 | 92.7% | — |
| 每股收益（稀释后） | $-0.26 | $0.43 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ASHHCSG
| Q4 25 | $386.0M | $466.7M | ||
| Q3 25 | $477.0M | $464.3M | ||
| Q2 25 | $463.0M | $458.5M | ||
| Q1 25 | $479.0M | $447.7M | ||
| Q4 24 | $405.0M | $437.8M | ||
| Q3 24 | $521.0M | $428.1M | ||
| Q2 24 | $544.0M | $426.3M | ||
| Q1 24 | $575.0M | $423.4M |
净利润ASHHCSG
| Q4 25 | $-12.0M | — | ||
| Q3 25 | $31.0M | $43.0M | ||
| Q2 25 | $-742.0M | $-32.4M | ||
| Q1 25 | $31.0M | $17.2M | ||
| Q4 24 | $-165.0M | — | ||
| Q3 24 | $17.0M | $14.0M | ||
| Q2 24 | $6.0M | $-1.8M | ||
| Q1 24 | $120.0M | $15.3M |
毛利率ASHHCSG
| Q4 25 | 27.2% | 15.4% | ||
| Q3 25 | 33.3% | 20.8% | ||
| Q2 25 | 28.5% | 0.6% | ||
| Q1 25 | 30.7% | 15.2% | ||
| Q4 24 | 27.4% | 13.4% | ||
| Q3 24 | 33.2% | 14.8% | ||
| Q2 24 | 34.2% | 9.7% | ||
| Q1 24 | 28.0% | 15.2% |
营业利润率ASHHCSG
| Q4 25 | -1.6% | 6.1% | ||
| Q3 25 | 12.8% | 12.3% | ||
| Q2 25 | -152.9% | -9.1% | ||
| Q1 25 | 10.6% | 5.3% | ||
| Q4 24 | -44.2% | 3.4% | ||
| Q3 24 | 6.1% | 4.4% | ||
| Q2 24 | -11.2% | -0.5% | ||
| Q1 24 | 3.7% | 5.0% |
净利率ASHHCSG
| Q4 25 | -3.1% | — | ||
| Q3 25 | 6.5% | 9.3% | ||
| Q2 25 | -160.3% | -7.1% | ||
| Q1 25 | 6.5% | 3.8% | ||
| Q4 24 | -40.7% | — | ||
| Q3 24 | 3.3% | 3.3% | ||
| Q2 24 | 1.1% | -0.4% | ||
| Q1 24 | 20.9% | 3.6% |
每股收益（稀释后）ASHHCSG
| Q4 25 | $-0.26 | $0.43 | ||
| Q3 25 | $0.83 | $0.59 | ||
| Q2 25 | $-16.21 | $-0.44 | ||
| Q1 25 | $0.65 | $0.23 | ||
| Q4 24 | $-3.50 | $0.15 | ||
| Q3 24 | $0.34 | $0.19 | ||
| Q2 24 | $0.12 | $-0.02 | ||
| Q1 24 | $2.39 | $0.21 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $304.0M | $168.0M |
| 总债务越低越好 | $1.4B | — |
| 股东权益账面价值 | $1.9B | $510.2M |
| 总资产 | $4.5B | $794.3M |
| 负债/权益比越低杠杆越低 | 0.74× | — |
8季度趋势，按日历期对齐
现金及短期投资ASHHCSG
| Q4 25 | $304.0M | $168.0M | ||
| Q3 25 | $215.0M | $177.5M | ||
| Q2 25 | $207.0M | $134.5M | ||
| Q1 25 | $168.0M | $114.8M | ||
| Q4 24 | $219.0M | $107.3M | ||
| Q3 24 | $300.0M | $103.8M | ||
| Q2 24 | $399.0M | $105.6M | ||
| Q1 24 | $439.0M | $104.9M |
总债务ASHHCSG
| Q4 25 | $1.4B | — | ||
| Q3 25 | $1.4B | — | ||
| Q2 25 | $1.4B | — | ||
| Q1 25 | $1.3B | — | ||
| Q4 24 | $1.3B | — | ||
| Q3 24 | $1.3B | — | ||
| Q2 24 | $1.3B | — | ||
| Q1 24 | $1.3B | — |
股东权益ASHHCSG
| Q4 25 | $1.9B | $510.2M | ||
| Q3 25 | $1.9B | $496.0M | ||
| Q2 25 | $1.9B | $477.0M | ||
| Q1 25 | $2.6B | $514.2M | ||
| Q4 24 | $2.6B | $499.9M | ||
| Q3 24 | $2.9B | $488.7M | ||
| Q2 24 | $3.0B | $471.4M | ||
| Q1 24 | $3.1B | $474.6M |
总资产ASHHCSG
| Q4 25 | $4.5B | $794.3M | ||
| Q3 25 | $4.6B | $804.3M | ||
| Q2 25 | $4.6B | $802.2M | ||
| Q1 25 | $5.2B | $823.0M | ||
| Q4 24 | $5.2B | $802.8M | ||
| Q3 24 | $5.6B | $805.8M | ||
| Q2 24 | $5.7B | $799.7M | ||
| Q1 24 | $5.9B | $803.9M |
负债/权益比ASHHCSG
| Q4 25 | 0.74× | — | ||
| Q3 25 | 0.73× | — | ||
| Q2 25 | 0.73× | — | ||
| Q1 25 | 0.52× | — | ||
| Q4 24 | 0.51× | — | ||
| Q3 24 | 0.47× | — | ||
| Q2 24 | 0.45× | — | ||
| Q1 24 | 0.42× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $125.0M | $17.4M |
| 自由现金流经营现金流 - 资本支出 | $111.0M | $16.0M |
| 自由现金流率自由现金流/营收 | 28.8% | 3.4% |
| 资本支出强度资本支出/营收 | 3.6% | 0.3% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $200.0M | $139.2M |
8季度趋势，按日历期对齐
经营现金流ASHHCSG
| Q4 25 | $125.0M | $17.4M | ||
| Q3 25 | $40.0M | $71.3M | ||
| Q2 25 | $115.0M | $28.8M | ||
| Q1 25 | $9.0M | $27.5M | ||
| Q4 24 | $-30.0M | $36.2M | ||
| Q3 24 | $80.0M | $4.3M | ||
| Q2 24 | $127.0M | $16.3M | ||
| Q1 24 | $54.0M | $-26.0M |
自由现金流ASHHCSG
| Q4 25 | $111.0M | $16.0M | ||
| Q3 25 | $6.0M | $70.0M | ||
| Q2 25 | $95.0M | $27.4M | ||
| Q1 25 | $-12.0M | $25.8M | ||
| Q4 24 | $-53.0M | $34.8M | ||
| Q3 24 | $42.0M | $2.9M | ||
| Q2 24 | $98.0M | $15.0M | ||
| Q1 24 | $20.0M | $-28.2M |
自由现金流率ASHHCSG
| Q4 25 | 28.8% | 3.4% | ||
| Q3 25 | 1.3% | 15.1% | ||
| Q2 25 | 20.5% | 6.0% | ||
| Q1 25 | -2.5% | 5.8% | ||
| Q4 24 | -13.1% | 7.9% | ||
| Q3 24 | 8.1% | 0.7% | ||
| Q2 24 | 18.0% | 3.5% | ||
| Q1 24 | 3.5% | -6.7% |
资本支出强度ASHHCSG
| Q4 25 | 3.6% | 0.3% | ||
| Q3 25 | 7.1% | 0.3% | ||
| Q2 25 | 4.3% | 0.3% | ||
| Q1 25 | 4.4% | 0.4% | ||
| Q4 24 | 5.7% | 0.3% | ||
| Q3 24 | 7.3% | 0.3% | ||
| Q2 24 | 5.3% | 0.3% | ||
| Q1 24 | 5.9% | 0.5% |
现金转化率ASHHCSG
| Q4 25 | — | — | ||
| Q3 25 | 1.29× | 1.66× | ||
| Q2 25 | — | — | ||
| Q1 25 | 0.29× | 1.60× | ||
| Q4 24 | — | — | ||
| Q3 24 | 4.71× | 0.31× | ||
| Q2 24 | 21.17× | — | ||
| Q1 24 | 0.45× | -1.70× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ASH
| Personal Care And Household | $123.0M | 32% |
| Other | $120.0M | 31% |
| Specialty Additives | $36.0M | 9% |
| Intermediates And Solvents | $31.0M | 8% |
| Personal Care | $30.0M | 8% |
| Life Sciences | $27.0M | 7% |
| Intermediates | $19.0M | 5% |
HCSG
| Dietary Services | $255.9M | 55% |
| Other | $210.8M | 45% |
